On Friday, New York-based startup Renalytix AI, maker of a clinical diagnostic that uses artificial intelligence to diagnose for kidney disease, landed $29 million in funding. This news coincides with Renalytix AI’s announcement that it will now be publicly traded on the London Stock Exchange.
Looking ahed, the company said the new money will be used to help it develop two products designed for...